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Abstract: Quinolones constitute a large class of antibacterial agents whose action is mediated through the formation of a 
ternary complex with DNA and either, DNA Gyrase or topoisomerase IV, resulting in the inhibition of DNA replication. 
In order to get a deeper insight into the features of the complex formation, we carried out docking studies of fifteen 
diverse quinolones to the cleaved topoisomerase IV-DNA complex. Docking studies were performed using the crystal 
structures of the cleaved complex with levofloxacin and moxifloxacin (pdb entries 3K9F and 2XKK, respectively) using 
the GOLD software. Ligands dock in positions similar to those of the crystal structures. Analysis of the results reveals that 
bound quinolones appear intercalated between the two nucleotides that are involved in the DNA cleavage and exhibit 
hydrogen bonds with Arg
117
 and, the latter mediated though a water molecule. Arg
117 
has not been described to be 
involved in resistance, since it is putatively involved in the enzymatic reaction and its mutation would be lethal for the 
organism. Mutants of Ser
79 
exhibit resistance to quinolones which can be explained by the loss of an important anchoring 
point. Interestingly, quinolone resistance observed in Asp
83
 mutants cannot be explained directly on the basis of the loss 
of a direct interaction, but could be explained on the basis of its involvement at the entrance of the ligands to their binding 
pocket since the residue is located at the mouth of the pocket. The results of the present study suggest that the 4-keto and 
3-carboxyl groups of the fluoroquinolones bind a Mg
2+
 before binding to the cleaved topoisomarase IV-DNA complex 
and use Asp
83
 for entry into the binding pocket. Accordingly, mutations that do not conserve the binding capacity for the 
quinolone-Mg
2+
 complex will prevent the binding of this class of ligands. The results we present here are also compared 
with the structure of PD0305970 a 2,4-dione active against the Ser
79
 and Asp
83
 mutants. 
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INTRODUCTION 
 Antibiotic resistance is a major public health concern of 
modern society. Infections caused by resistant pathogens 
have serious consequences, including an increased risk of 
death, hampering of infectious disease control and raising 
the threat of a return to the pre-antibiotic era [1]. Quinolones 
constitute a large class of synthetic antimicrobial agents with 
a 17% share of the world antibiotic market [2]. They are 
effective for the treatment of many types of infectious 
diseases caused by bacteria, being clinically used to treat 
infections of the urinary tract and respiratory system mainly, 
although they are also used for the treatment of sexually 
transmitted diseases, bone and joint infections or typhoid 
fever [3, 4]. Quinolones exhibit properties of the ideal 
antibiotic: high potency, a broad spectrum of activity, good 
bioavailability, oral and intravenous formulations, high 
serum levels, a large volume of distribution indicating 
concentration in tissues and a potentially low incidence of 
side-effects. However, after some years of quinolone use, 
resistance in Enterobacteriaceae has become common, wide 
spread and non-clonal [5] forcing the need to develop new 
analogs. 
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 From the chemical point of view, quinolone is a generic 
term, used loosely to refer to different chemical structures 
that have a 4-oxo-1, 4-dihydroquinoline skeleton shown in 
Fig. (1), most often with a carboxylic acid attached at 
position 3 [6, 7]. Nalidixic acid (see Fig. 1) was the first 
member of this family to be released in the early sixties, with 
a moderate antibacterial activity and narrow Gram-negative 
spectrum. The substitution of a piperazine ring at position R7 
and the addition of a fluorine atom at position R6, resulted in 
an increase of potency and spectrum of activity to Gram-
positive bacteria, giving rise to a second generation of 
quinolones, about a decade later. A third generation came a 
few years later with the popular addition of a cyclopropyl 
group at position R1 together with substitution of methoxy 
or chlorine moieties at position R8. The cyclopropyl moiety 
enhances potency and has some effects on pharmacokinetics. 
Different structure-activity studies have provided evidence 
of the effect of different substitutions on the 4-quinolone 
scaffold. Thus, it is known that bulky substituents at position 
R2 lower the microbiological activity due to steric 
hindrance. Only sulfur, incorporated into a small ring as in 
the case of the thiazetoquinolones, has been able to replace 
hydrogen at the R2 position. Substituents at R5 position 
appear to have the capacity to alter overall steric 
configuration (planar structure) of the molecule, which is 
why changes here are thought to affect activity. Modestly 
sized additions, such as an amino, hydroxyl, or methyl 
groups can markedly increase in vitro activity against Gram-
positive bacteria as well as enhance potency. It is also known 
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that a fluorine atom at position R6 controls bacterial potency 
or that the presence of a bulky ring at position R7 controls 
potency spectrum and pharmacokinetics. Finally, the 
heterocycle scaffold can also be modified. Thus, when 
position R8 is changed for nitrogen, the family of 
napthylridines produced exhibit also high antibiotic activity. 
Similarly, quinazolines, quinazolinediones [8-10] or 
isothioquinolones [11] have also proved to have high 
antibiotic activity. 
 The therapeutical targets of quinolones are two bacterial 
type II topoisomerases: DNA gyrase and topoisomerase IV 
[12]. Type II topoisomerases regulate the overwinding or 
underwinding of DNA by creating transient breaks on the 
two DNA strands (known as the cleaved complex) and reseal 
them, after passing another unbroken DNA double strand 
through it. Both are tetrameric proteins formed by two 
(duplicated) subunits. In the case of gyrase they are called 
GyrA and GyrB subunits, whereas in the case of 
topoisomerase IV they are called ParC and ParE subunits. 
Gyrase tends to be the primary target in Gram-negative 
bacteria, while the activity of topoisomerase IV is 
preferentially inhibited by most quinolones in Gram-positive 
organisms, but this may vary with the drug. Quinolones bind 
to the transient topoisomerases-DNA complex preventing 
religation of DNA ends. The subsequent release of DNA 
from protein constraints fragments chromosomes, causing 
cell death [13]. 
 Regular uses of quinolones in the past more than forty 
years have raised resistant strains against them. Resistance 
arises from mutations that either alter drug uptake and efflux 
or affect binding interactions between the target enzyme and 
the quinolones, being this latter the main mechanism of 
bacterial resistance [14]. Mutations affecting the binding of 
quinolones more frequently affect a region of the protein 
called quinolone-resistant determining region located either 
in the N-terminal domains of ParC and GyrA or in the C-
terminal domain of ParE. In ParC subunit of Streptococcus 
pneumonia topoisomerase IV, the most common mutations 
are S79A, S79W and D83Y, D83G, D83H, D83N, and 
D83A [15]. 
 Knowledge of the structural features that control ligand-
receptor interaction at the atomic level is crucial for 
designing new quinolones to be active to resistant strains. 
The recent release of the crystallographic structures of the 
cleaved topoisomerase IV-DNA-quinolone ternary 
complexes with levofloxacin shown in Fig. 1 (pdb entry 
3K9F) [16]; moxifloxacin (see Fig. 1) (pdb entry 2XKK) 
[17], ciprofloxacin, shown in Fig. 1 (pdb entry 2XCT) [18] 
and PD0305970, shown in Fig. 1 (pdb entry 3LTN) [16] 
have contributed to a better understanding of quinolone 
mechanism of action. Superimposition of the 
crystallographic structures of the four cleaved DNA-
topoisomerase IV-quinolone complexes (shown in Fig. 3), 
shows the ligands occupying the same binding pocket and 
oriented in the same pose, suggesting that the modification 
from a 3-carboxylic acid, 4-ketone to a 2,4-dione does not 
alter the binding mode of the ligand to the target protein. 
Bound quinolones are found intercalated between the two 
nucleotides involved in the DNA cut, and oriented in such a 
way that some moieties interact with specific residues of the 
ParC subunit, including Arg
117 
and Ser
79
. Specifically, the 
four molecules exhibit a hydrogen bond with Arg
117
: in the 
case of the dione involving the carbonyl located in R2, 
whereas in the case of the fluoroquinolones the carboxylic 
group in R3. The three fluoroquinolones also exhibit a 
hydrogen bond interaction with the side chain of Ser
79
. In the 
case of ciprofloxacin is a direct interaction, whereas in the 
case of levofloxacin and moxifloxacin it is mediated through 
a water molecule. Furthermore, analysis of the moxifloxacin 
and ciprofloxacin structures reveals that the Ser
79 
side chain 
is involved in an interaction with a divalent ion (Mg
2+ 
in the 
former and Mn
2+ 
in the latter) mediated through a water 
molecule. No divalent ion is found in the structure with 
levofloxacin [16]. On the opposite region of the ligand 
structure, the bulky moiety in R7 projects into a large 
solvent-accessible volume. This region in topoisomerase IV 
contains several polar interconnected residues, including 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. (1). General scheme and numbering of the 4-oxo-1,4-dihydroquinoline scaffold and the chemical structures of different quinolone 
analogs: Nalidixic acid; levofloxacin; moxifloxacin; ciprofloxacin; PD0305970. 
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Asp
435
, Glu
474
, Glu
475
 and Arg
456
 that create an environment 
adequate to host a polar/charged moiety. In fact, PD0305970 
takes advantage of it with an amine group that is found 
interacting with Glu
474 
and the backbone carbonyl of Arg
456
. 
Finally, all the structures show one of the two catalytic Mg
2+ 
coordinated by residues Asp
508
 and Asp
506
 [19]. 
 In spite of the wealth of information provided by the 
crystallographic structures, there are uncertainties 
surrounding the exact details of the quinolone-DNA and 
quinolone-protein interaction in part associated with the 
degree of resolution of the different structures. In addition, it 
is very likely that different quinolones will have different 
specific interactions with their target, and these will also 
vary depending on the target (gyrase or topoisomerase IV). 
An intriguing question remaining regards the role played by 
Mg
2+
 in quinolone binding. Thus, in addition to its well 
established role for DNA cleavage [20, 21], it is known that 
the divalent ion is necessary for quinolone action [21, 22]. In 
fact, two of the three crystallographic structures of the 
cleaved topoisomerase IV-DNA-quinolone ternary complex 
available show a divalent ion (Mn
2+
 in the complex with 
ciprofloxacin) bound to the C3/C4 keto acid moiety of the 
quinolone molecule with four water molecules saturating the 
rest of its octahedral coordination shell. Inspection of the 
structures suggests that the loss of activity of quinolones 
when Ser
79
 is mutated can be attributed to the corresponding 
loss of the interaction serine side chain-water-ion [17, 22]. 
However, it is not clear if this hypothesis can be extended to 
explain the observed resistance when Asp
83
 is mutated? 
Furthermore, why the ion bound to the quinolones is not 
directly bound to Ser
79
 and Asp
83 
side chains in contrast to 
the one found in the catalytic site? Why the crystallographic 
structure of the complex with levofloxacin does not exhibit 
any ion bound to the quinolone? 
 Thus, a deeper understanding of the structure-activity 
relationships exhibited by this family of compounds, as well 
as characterization of the structural reasons for certain 
mutations to make strains resistant or the mechanism of 
quinolone binding at the atomic level, will be useful for 
designing new analogs. Computational techniques represent 
an adequate alternative and companion to experimental 
methodologies in providing insightful atomic level structural 
information and interactions knowledge. Accordingly, we 
have analyzed the structural features of 15 complexes of 
different quinolone analogs bound to the cleaved DNA-
topoisomerase IV and the results of this comparative analysis 
are reported in the present work. These molecules have been 
selected to cover the maximum structural diversity of the 
quinolones so far described. 
METHODS 
 The ternary cleaved of DNA-topoisomerase IV structures 
from Streptococcus pneumoniae and Acinetobacter 
baumannii with levofloxacin and moxifloxacin bound (pdb 
entries 3K9F and 2XKK) respectively, (with their respective 
ligands removed) were used as templates for the modeling 
studies described in the present work. The templates were 
pre-processed using the Molecular Operating Environment 
(MOE) [23] software, including assignment of side change 
ionization states, addition of missing residues and 
hydrogens. Crystallographic waters were kept to perform the 
present study. In order to characterize the features of the 
binding pocket, the MOE software was used to compute 
interaction maps using probes of different nature. Maps 
produced by a hydrophobic, proton acceptor and proton 
donor probes were used to supervise the results of 
subsequent docking studies. 
 Docking of a group of diverse fifteen fluoroquinolones 
(including levofloxacin, ciprofloxacin and moxifloxacin) 
was carried out. The group of quinolones includes 
clinafloxacin, garenoxacin, gatifloxacin, gemifloxacin, 
ofloxacin, prulifloxacin, sitafloxacin, trovafloxacin, 
temafloxacin, grepafloxacin, sparfloxacin, and tosufloxacin, 
whose structures are shown in Fig. (2). Fluoroquinolones 
were docked into the binding pocket of the templates using 
the Genetic Optimization for Ligand Docking software 
(GOLD) version 5.1 with the goldscore scoring function [24, 
25]. 
 In addition, in order to understand the effect of resistant 
mutations on quinolone binding, mutants S79A and D83Y as 
well as the double mutation (S79A+D83Y) were generated 
using the topoisomerase IV-moxifloxacin complex (pdb 
entry 3K9F). These proteins were used to construct fifteen 
different complexes of each, using the ligands of Fig. (2) 
together with moxifloxacin, ciprofloxacin and levofloxacin. 
Docking studies were carried out as described above. 
RESULTS AND DISCUSSION 
 We carried out docking of the twelve analogs listed in 
Fig. (2) together with moxifloxacin, ciprofloxacin and 
levofloxacin, using the structures of pdb code 2XKK and 
3K9F as target macromolecules. The main difference 
between the two structures is the lack of a bound Mg
2+ 
in the 
fluoroquinolone site in the latter. One of the outcomes of this 
study is that there are no differences when the structures are 
docked to either protein, suggesting that the quinolone-
bound Mg
2+
 ion is not crucial for an adequate positioning of 
the ligand in the binding pocket. As found in the 
crystallographic structures, the quinolone structure exhibits a 
stacking interaction with the nucleotides involved in the 
DNA cut. In addition, the 3-carboxyl group establishes a 
direct hydrogen bond with Arg
117
and a water mediated 
hydrogen bond with the residue Ser
79
. 
Structure-Activity Relationships 
 A comparative analysis of the docked structures permits 
to identify common stereoelectronic features in each of the 
different substitutions on the quinolone scaffold, once the 
ligands are superimposed in their actual positions inside the 
binding pocket. Thus, when a hydrophobic probe is used to 
scan the binding pocket without any ligand, three areas are 
found for the preferential location of a hydrophobic moiety. 
First, the region where the fused rings sit intercalated 
between the nucleotides. Second, an area in the 
neighborhood of position R1, which justifies the use of 
cyclopropane as substituent in nine of the analogs studied. In 
addition to cyclopropane, other hydrophobic moieties, like 
difluorobenzene found in trovafloxacin, temafloxacin or 
tosufloxacin or the thiazetoquinolone skeleton, as in 
prulifloxacin, fit well within the hydrophobic area as can be 
seen in Fig. (4). The third area for favorable hydrophobic 
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interactions which have been largely exploited lies in the 
neighborhood of the R7 substituent, distant from the fused 
rings. In both crystal and docked structures, bulky 
substituents in R7 occupy a large pocket created between the 
DNA and the ParE subunit. In contrast, in PD0305970 the 
substitution ion R7 exploits an area with a few polar 
conserved residues. This indicates that bulkier substitutions 
are possible and can be harnessed to promote ligand-enzyme 
interactions at this position as seen in some of the new 
fluoroquinolones [26]. SAR studies have proven that a bulky 
substituent at R7 tends to lead to reduced side effects, 
improved potency and in vivo efficacy against Gram positive 
species [10, 27-30]. 
 Few substitutions have proven to be successful in 
position R5. Possible substituents in this position cannot be 
bulky because it would interfere the stacking interaction 
between the drug and the nucleotides. Thus, a methyl group 
like in grepafloxacin or an amine group like in sparfloxacin 
have been credited with an increase in drug potency against 
Gram positive bacteria [31]. 
 In regard to the R6 substituents, a fluorine atom in this 
position has been demonstrated to be important for 
quinolone binding. Since quinolone binding can be largely 
explained on the basis of a stacking interaction of the 
quinolone molecule with the flanking nucleotides, 
enhancement of this interaction will improve the affinity of 
the ligand. Indeed, an important component of this binding is 
due to the quadrupole-quadrupole interactions, so an 
electronegative substituent with capacity to modulate the 
quadrupole moment of the ligand, will increase these 
interactions. On the other hand, as discussed for position R5, 
substituents cannot be bulky due to steric contacts with 
neighboring nucleotides. Accordingly, fluorine fulfills all the 
requirements and the reason to have been difficult to 
substitute. 
 Among many structural modifications investigated in R8 
position, few substituents such as fluoro, chloro, methyl, and 
methoxy groups render an increase in antibacterial activity, 
especially against Gram-positive bacteria and enhanced  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. (2). Chemical structures of the fifteen quinolones selected for the present study. 
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Fig. (3). Superimposition of the crystal structures 3K9F, 2XKK and 3LTN showing the overlapping between the different quinolones: 
levofloxacin (orange), moxifloxacin (navy blue), ciprofloxacin (yellow) and PD0305970 (green), respectively. For interpretation of 
references to color in this figure legend, the reader is referred to the web version of this paper. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. (4). Hydrophobic map of the quinolones (moxifloxacin in green, prulifloxacin in pink, levofloxacin in yellow and Tosufloxacin in dark 
orange) showing hydrophobic area (in silver) around the R1 and R5 of the quinolones (and nearby receptor atoms). For interpretation of 
references to color in this figure legend, the reader is referred to the web version of this paper. 
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potency against anaerobes [32]. Furthermore, the influence 
of 5-amino group in sparfloxacin has been reported to 
depend on the substitution pattern of R8 and R1. Thus, while 
we could not find direct structural interaction between the 
substituents at these positions and the receptor, their self-
association may well be their contribution to the ligand 
activity. In regard to position R2, the models show that 
although there is enough room to host different chemical 
moieties, there are no side chains neither of the protein or the 
DNA, available to produce favorable interactions with the 
ligand in order to improve the affinity of these analogs. The 
only quinolones described with a substitution in this position 
are the thiazetoquinolones. The favorable role of this moiety 
can be explained on the basis of the bulkiness of the sulphur 
atom, capable to establish a hydrophobic interaction with the 
two nucleotides flanking the quinolone binding site. 
Quinolone Binding 
 In order to assess the importance of different interactions 
acting on quinolone binding, we performed docking studies 
of the fifteen analogs onto the DNA with the protein 
removed and vice versa, onto the protein with the DNA 
removed, using the same structures as templates. When 
docking the quinolones on the DNA structure, it can be seen 
that they accommodate intercalated between the two 
nucleotides involved in the DNA cut, but adopt 
systematically a pose in different orientation in regard to the 
crystallographic structure. This suggests that the stacking 
interactions are strong enough to bind the ligands, but unable 
to orient them properly, needing additional anchoring points 
for a correct docking orientation that is provided by the 
protein. On the other hand, when the docking is performed 
on the protein alone, the molecule accommodates on top of 
residues Ser
79
 and Asp
83 
as had been observed previously 
[33]. Taking these observations together with the known 
experimental results available, it is reasonable to consider 
that the molecule does not bind to any of the two 
macromolecules prior to complex formation [34, 35]. 
 Although Mg
2+ 
is necessary for the catalytic action of 
topoisomerase, its role in quinolone binding is enigmatic. It 
is surprising that one of the structures does not exhibit the 
ion coordinated with levofloxacin. Since the docking study 
of the different quinolones described above provides the 
same results with or without the presence of the magnesium 
ion, it could be thought that the ion is not important for the 
pose taken by the ligand when bound. This result raises the 
question whether the ion is already in the protein prior to 
ligand binding or it is borne by the quinolones. In fact, 
quinolones are important chelating agents with high affinity 
for different ions, including Mg
2+ 
[36, 37]. Moreover, the 
fact that EDTA reverses the action of quinolones can be 
explained by its sequestering capacity that would limit the 
number of quinolone-Mg
2+
 molecules available in solution, 
reversing the binding [38]. In order to shed some light into 
this question we proceeded to identify favorable sites for a 
magnesium ion to sit in the binding pocket of the transient 
toposiomerase-DNA complex by computing the interaction 
map inside the binding pocket using the structures 3K9F and 
2XKK with the quinolone removed, by means a magnesium 
probe. Inspection of the interaction maps permits to identify  
 
the site of the catalytic magnesium but not that of the 
quinolone. However, when the maps are computed with the 
quinolone bound a favorable site close to the C3/C4 keto 
acid moiety is identified. Moreover, for the Mg
2+
to bind to 
the protein before ligand binds, it is not clear why it does not 
exhibit direct interactions with side chains of the receptor 
and only water mediated in contrast what is found in the 
catalytic site, where the ion binds directly to Asp
508
 and 
Asp506. Furthermore, this hypothesis provides an explanation 
to antibiotic resistance produced by mutations on Asp
83
as 
explained below. 
Effect of Mutations on Ligand Binding 
 In regard to the S79A mutation, docking structures onto 
the mutant protein reveal that the non-polar side chain of 
alanine prevents the interaction with the ligands and/or to the 
magnesium ion, with the subsequent loss of affinity. This is 
not observed in the 2,4-dione ligands, since Ser
79
 is not 
involved in a direct interaction with the ligand and the 2,4-
diones do not exhibit chelating properties [17, 22]. 
 In the case of the D83Y mutant the effect of the mutation 
cannot be explained on the basis of a loss of affinity of the 
ligand, since the tyrosine side chain could hold a hydrogen bond 
with the quinolone. An alternative explanation can be argued by 
inspection of the protein surface. When the solvent accessible 
surface area of the protein is plotted, Asp
83
is clearly identified at 
the mouth of the binding pocket like gatekeeper (see Fig. 5). 
Thus, it can be hypothesized that this residue is involved in the 
initial recognition step of the ligand. Accordingly, for the 
recognition step to be successful, quinolones should bear a 
charge complementary to aspartate, that could be provided by 
the Mg
2+
 bound to the quinolones providing a net positive 
charge. In the case of the mutant D83Y, although the side chain 
is bulkier it does not impede the binding of the 2,4-dione 
analogs. Thus, it could be thought that since the tyrosine side 
chain at physiological pH does not exhibit a negative charged 
side chain, there will not be a favorable interaction with Mg
2+
, 
impeding the initial binding step. 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. (5). Mouth of the putative entry point of quinolones to the 
cleaved complex topoisomarase IV-DNA shown in light blue the 
location of Ser
79
 and Asp
83
. For interpretation of references to color 
in this figure legend, the reader is referred to the web version of this 
paper. 
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CONCLUSIONS 
 In this work we performed molecular modeling studies of 
the binding features of quinoloes using the available crystal 
structures of the topoisomerase IV-DNA cleaved complex 
with levofloxacin and moxifloxacin (pdb entries 3K9F and 
2XKK, respectively) to account for the known structure-
activity features of the quinolones and explain subsequently 
the resistance arose from amino acid alteration in the target 
enzymes, addressing simultaneously the role of Mg
2+
 in the 
process of quinolone binding. Specifically, we performed 
docking studies of a series of fifteen quinolones using both 
crystallographic structures alternatively. Analysis of the 
docked structures reveals that the binding of the different 
quinolones does not differ much from the poses of 
levofloxacin and moxifloxacin found in the crystal 
structures. Moreover, bound orientation of the ligands is not 
altered by the presence or not of a quinolone Mg
2+
, 
suggesting that the magnesium ion may already be bound to 
the quinolone before binding to the enzyme. This hypothesis 
provides an explanation for the resistance exhibited by 
different Asp
83 
mutants. Since the residue is located at the 
entrance of the binding pocket, it could be considered this 
residue to be putatively involved in the early recognition step 
of quinolones being able to bind to the quinolone-Mg
2+
 
complex. 
 The importance of Arg
117
 and Ser
79
 for quinolone binding 
is reinforced by the computational work of the present 
report. Interestingly, the former is putatively involved in the 
mechanism of the enzymatic reaction and its mutation would 
be lethal, whereas the latter has been found mutated 
providing quinolone resistance. Comparison with the 
structure of PD0305970, a 2,4-dione analog was also 
performed. This compound is active against mutants at 
positions Ser
79
 and Asp
83
. In the case of the former it can be 
explained because its interaction with the ligand is not as 
important as in quinolones. In the case of the latter, it 
suggests that this ligand does not require this amino acid for 
entry to the binding pocket, possibly due to the lack of 
chelating capacity of the ligand. 
 The key to understand quinolone action lies on our 
knowledge of the binding process. Thus, the future of 
quinolone research is entwined with the detailed 
understanding of the formation of quinolone-protein-DNA 
complex. The present study also raises a question on the 
future of quinolones as therapeutic agents. Knowledge of the 
structure of the complex and a plausible mechanism of 
binding provides us with important information to design 
new quinolones with improved drug-target interactions. 
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